Shouyao Holdings (Beijing) Co. Ltd. A (688197) - Total Liabilities

Latest as of March 2026: CN¥107.48 Million CNY ≈ $15.73 Million USD

Based on the latest financial reports, Shouyao Holdings (Beijing) Co. Ltd. A (688197) has total liabilities worth CN¥107.48 Million CNY (≈ $15.73 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shouyao Holdings (Beijing) Co. Ltd. A net asset momentum to track the company's year-over-year net asset growth rate.

Shouyao Holdings (Beijing) Co. Ltd. A - Total Liabilities Trend (2019–2025)

This chart illustrates how Shouyao Holdings (Beijing) Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.

Shouyao Holdings (Beijing) Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Shouyao Holdings (Beijing) Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Vina Concha To
SN:CONCHATORO
Chile CL$916.11 Billion
Guangzhou Hongli Opto Electron
SHE:300219
China CN¥3.36 Billion
Formosa International Hotels Corp
TW:2707
Taiwan NT$7.09 Billion
Suntront Tech
SHE:300259
China CN¥619.42 Million
Neurogene Inc
NASDAQ:NGNE
USA $25.36 Million
LSI Industries Inc
NASDAQ:LYTS
USA $148.21 Million
XOMA Royalty Corporation
NASDAQ:XOMA
USA $158.96 Million
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
China CN¥7.72 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Shouyao Holdings (Beijing) Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688197 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shouyao Holdings (Beijing) Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shouyao Holdings (Beijing) Co. Ltd. A (2019–2025)

The table below shows the annual total liabilities of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥111.05 Million
≈ $16.25 Million
-1.91%
2024-12-31 CN¥113.21 Million
≈ $16.57 Million
+24.20%
2023-12-31 CN¥91.16 Million
≈ $13.34 Million
-1.70%
2022-12-31 CN¥92.73 Million
≈ $13.57 Million
+63.62%
2021-12-31 CN¥56.67 Million
≈ $8.29 Million
+58.70%
2020-12-31 CN¥35.71 Million
≈ $5.23 Million
-19.44%
2019-12-31 CN¥44.33 Million
≈ $6.49 Million
--

About Shouyao Holdings (Beijing) Co. Ltd. A

SHG:688197 China Biotechnology
Market Cap
$710.32 Million
CN¥4.85 Billion CNY
Market Cap Rank
#10462 Global
#2800 in China
Share Price
CN¥32.64
Change (1 day)
-1.33%
52-Week Range
CN¥30.37 - CN¥55.94
All Time High
CN¥66.15
About

Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of innovative drugs in China. The company offers drugs for various indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, … Read more